PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trialFlorian Lordick, J. R. Siewert, Katja Ott et al.|The Lancet Oncology|2007Cited by 808
Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric JunctionKatja Ott, Jörg‐Rüdiger Siewert, Wolfgang Weber et al.|Journal of Clinical Oncology|2006Cited by 464
Radiotheranostics: a roadmap for future developmentKen Herrmann, Ralph Weissleder, Markus Schwaiger et al.|The Lancet Oncology|2020Cited by 306
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022Silke Gillessen, Ken Herrmann, Ross Eeles et al.|European Journal of Cancer|2023Cited by 156
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer EntitiesWolfgang P. Fendler, Rainer Hamacher, Kim M. Pabst et al.|Clinical Cancer Research|2022Cited by 145